Special Issue

New Generation Imaging in Oncology 2.0

Message from the Guest Editors

The introduction of positron emission tomography (PET) imaging, in oncology has already changed the clinical outcomes and therapeutic management of oncological patients. Several PET radiopharmaceuticals have been proposed in oncology over the last decade, and these diagnostic techniques are now currently placed under the umbrella term “new-generation imaging”.
The most successful approaches proposed for PET imaging, other than FDG-PET, have been receptorial tracers targeting the somatostatin receptors (SSRs) and the prostate-specific membrane antigen (PSMA), proposed to investigate neuroendocrine tumors and prostate cancer, respectively. However, FDG-PET still holds an innovative position when considering its application to evaluate the efficacy of new-generation therapeutic approaches in oncology, like immunotherapy. Finally, the application of radiomics in PET imaging is an emerging field.
This Special Issue aims to collect innovative studies regarding the translational imaging of new-generation PET imaging in oncology. Pre-clinical studies and comprehensive reviews regarding these innovative diagnostic and therapeutic approaches will be considered.

Guest Editors

Dr. Francesco Ceci
Nuclear Medicine Division, European Institute of Oncology (IEO) IRCCS, Milan, Italy

Dr. Marcus Unterrainer
Department of Radiology, Klinikum der Universität München, Munich, Germany

Dr. Michel Eisenblätter
King’s College, University of Freiburg, London, UK

Deadline for manuscript submissions

closed (31 July 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/84673

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).